Free Trial

Co-Diagnostics Q2 2023 Earnings Report

Co-Diagnostics logo
$0.31 -0.01 (-3.84%)
As of 03:59 PM Eastern

Co-Diagnostics EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.24
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Co-Diagnostics Revenue Results

Actual Revenue
$0.20 million
Expected Revenue
$0.75 million
Beat/Miss
Missed by -$550.00 thousand
YoY Revenue Growth
N/A

Co-Diagnostics Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Co-Diagnostics Earnings Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
See More Co-Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Co-Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Co-Diagnostics and other key companies, straight to your email.

About Co-Diagnostics

Co-Diagnostics (NASDAQ:CODX), a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

View Co-Diagnostics Profile

More Earnings Resources from MarketBeat